Southern Star Research Institute

San Antonio, Texas 78229

9 studies enrolling now · 12 studies all time

What they study most

Colitis, Ulcerative, Constipation, Crohn Disease, Crohn's Disease, Diabetic Gastroparesis, Diarrhea, Idiopathic Gastroparesis, Irritable Bowel Syndrome, Obesity or Overweight, Ulcerative Colitis, Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate

Studies at this site

• A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease — Recruiting now
• A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) — Recruiting now
• A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) — Recruiting now
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Recruiting now
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Recruiting now
• LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: — Recruiting now
• A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease — Recruiting now
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• Confirmatory Clinical Study in Active Ulcerative Colitis — Recruiting now
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Running, not enrolling
• A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis — Completed